Aldeyra Therapeutics, Inc. (ALDX)
Aldeyra Therapeutics is a Concord, Massachusetts biotech developing drug candidates for eye and other immune system diseases. It last closed at $0.69 on Nov 17, up 2.18% on the day.
Key Stats
Last 12 monthsNot reported for this period.
From ALDX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 1 analyst who set a price target on ALDX in the past 90 days. The average target is $9.00, with a high of $9.00 and a low of $9.00, compared with the last close of $0.69.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 29 | BTIG | Reiterated | Buy | $9 |
| Mar 18 | HC Wainwright & Co. | Downgrade | Hold | $2 |
Technical Analysis
The stock sits between its 20 and 50 day averages. It is 190% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 45). The nearest support is the Pivot at $0.69, and the nearest resistance the swing high (Nov 4) at $0.70.
| RSI (14) | 45.25 | Middle of its range | Neutral |
| MACD | -0.07 | Above its signal line | Bullish |
| Stochastic | 75.7 | Middle of its range | Neutral |
| ADX (14) | 30.2 | Trending up | |
| Williams %R | -13.1 | Oversold below −80, overbought above −20 | Overbought |
| CCI (20) | 121.8 | Oversold below −100, overbought above 100 | Overbought |
| Rate of change | +11.8% | Change over 10 sessions | Bullish |
| ATR (14) | $0.08 | Typical daily range, 10.9% of price |
| RSI (14) | 29.00 | Oversold below 30 | Oversold |
| MACD | -0.48 | Above its signal line | Bullish |
| Stochastic | 12.0 | Near the bottom of its range | Oversold |
| ADX (14) | 38.9 | Trending down | |
| Williams %R | -84.5 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -99.8 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −48.2% | Change over 10 sessions | Bearish |
| ATR (14) | $0.27 | Typical daily range, 39.2% of price |
What happened before
See how ALDX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How ALDX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.
Whale Options Flow
90DNo whale options trades in ALDX in the last 90 days.
ALDX Institutional Ownership
Full report →- ▼35 buying vs 70 selling
- ▼Held by funds -9.6 pts
- ▼Funds holding -12
- ▼Superinvestors: 0 added, 4 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 96 | 108 | −11.1% |
| In funds' top 10 | 0 | 1 | −100.0% |
| Held by funds | 51.4% | 61.0% | −9.6 pts |
| New / increased | 13 / 22 | 18 / 31 | −28.6% |
| Reduced / sold out | 45 / 25 | 43 / 37 | −12.5% |
| Put/call ratio | 0.00 | 0.00 | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ALDX is in one of them and how their past ALDX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ALDX in an article yet. Here's the latest on the wider market.
About Aldeyra Therapeutics
Aldeyra Therapeutics is a biotechnology company based in Concord, Massachusetts, that develops drug candidates for diseases of the immune system. Its approach uses a family of small molecules called RASP modulators, which act on many proteins at once rather than a single target. Its most advanced candidate, reproxalap, is being studied for dry eye disease and allergic conjunctivitis, and the company is also developing treatments for retinal conditions. It has no approved products yet and plans to sell any future drugs directly or through partners.
- Headquarters
- Concord, MA



